CHARM: Chronic Hepatitis B Antihepadnaviral Resistance Mutation Study (CHARM)
|Study Design:||Observational Model: Cohort
Time Perspective: Cross-Sectional
|Official Title:||Study of Acquired Viral Mutations in Chronic Hepatitis B Patients on Antihepadnaviral Therapy|
- Descriptive statistics for clinical and viral characteristics of the study population [ Time Frame: Single timepoint (blood draw) ] [ Designated as safety issue: No ]
|Study Start Date:||February 2008|
|Study Completion Date:||November 2008|
|Primary Completion Date:||October 2008 (Final data collection date for primary outcome measure)|
This is a naturalistic cross-sectional study of chronic hepatitis B subjects receiving nucleoside or nucleotide antihepadnaviral therapy.
It is anticipated approximately 800 subjects will be recruited at 20 Australian sites. Data will be collected on the study subjects and analyses performed to describe factors contributing to the emergence of viral mutations in Australian patients with chronic hepatitis B.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00645736
|Gilead Sciences Pty Ltd|
|East Melbourne, Victoria, Australia, 3002|
|Study Director:||Howard Wraight||Gilead Sciences Pty Ltd|